SUNPHARMA Sun Pharmaceuticals Industries Ltd Product Launches Announcement 2024 - Results of Phase III Trial Results of Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024 revealed statistically significant and clinically meaningful benefits, showing promise as a potential therapeutic option..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Sun Pharmaceuticals Industries Ltd